P-gp/CYP3A4相互作用药物对NOACs疗效与安全性的荟萃分析
该荟萃分析纳入15项研究,评估P-gp/CYP3A4相互作用药物对房颤患者NOACs疗效与安全性的影响。结果显示,联用P-gp/CYP3A4抑制剂显著增加大出血和全因死亡风险,而卒中/系统性栓塞风险无显著差异。提示临床需密切监测此类联用患者。
要点
- 联用P-gp/CYP3A4抑制剂增加大出血(RR 1.10)和全因死亡(RR 1.14)风险。
- 联用胺碘酮降低血栓栓塞风险(RR 0.75)但增加死亡风险(RR 1.21)。
- 联用维拉帕米或地尔硫䓬增加大出血风险(RR 1.64)。
核心结论
- 房颤患者联用P-gp/CYP3A4抑制剂时,NOACs的大出血和死亡风险显著升高,需密切监测。
主要发现
- 联用P-gp/CYP3A4抑制剂者大出血风险RR 1.10(95%CI 1.01-1.19),全因死亡风险RR 1.14(95%CI 1.05-1.23),卒中/系统性栓塞RR 0.88(95%CI 0.77-1.01),颅内出血RR 0.89(95%CI 0.68-1.15),胃肠道出血RR 1.09(95%CI 0.91-1.30)。
- 联用胺碘酮者血栓栓塞风险RR 0.75(95%CI 0.61-0.92),大出血风险RR 0.92(95%CI 0.80-1.07),死亡风险RR 1.21(95%CI 1.05-1.39)。
- 联用维拉帕米或地尔硫䓬者大出血风险RR 1.64(95%CI 1.31-2.06),血栓栓塞风险RR 1.10(95%CI 0.75-1.61),死亡风险RR 1.01(95%CI 0.77-1.33)。
临床怎么用
- 对联用P-gp/CYP3A4抑制剂的NOAC治疗房颤患者,应加强出血和死亡风险监测。
- 联用胺碘酮时注意死亡风险升高,联用维拉帕米或地尔硫䓬时重点防范大出血。
局限性
- 仅1项研究涉及P-gp/CYP3A4诱导剂,相关证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: P-glycoprotein (P-gp) and CYP3A4-interacting drugs influence plasma levels of non-vitamin K antagonist oral anticoagulants (NOACs). However, the clinical relevance is questioned. Therefore, the impact of pharmacokinetically-interacting drugs on the effectiveness and safety of NOACs in patients with atrial fibrillation (AF) was investigated. METHODS: A meta-analysis was performed based on randomized controlled trials and observational studies retrieved from Pubmed and Embase that investigated the impact of concomitantly used P-gp/CYP3A4-interacting drugs on the risk-benefit profile of NOACs in AF patients. RESULTS: Fifteen studies were included, investigating 21 711 and 306 421 NOAC-treated AF patients with and without P-gp/CYP3A4 inhibitor use respectively, while only 1 study included P-gp/CYP3A4 inducers. In NOAC-treated AF patients, concomitant use of P-gp/CYP3A4 inhibitors was associated with significantly higher major bleeding (relative risk [RR] 1.10, 95% confidence interval [CI; 1.01-1.19]) and all-cause mortality risks (RR 1.14, 95%CI [1.05-1.23]) compared to not using P-gp/CYP3A4 inhibitors, while the risks of stroke/systemic embolism (RR 0.88, 95%CI [0.77-1.01]), intracranial bleeding (RR 0.89, 95%CI [0.68-1.15]) and gastrointestinal bleeding (RR 1.09, 95%CI [0.91-1.30]) were not significantly different. Concomitant use of amiodarone with NOACs was associated with lower thromboembolic (RR 0.75, 95%CI [0.61-0.92]), similar major bleeding (RR 0.92, 95%CI [0.80-1.07]) but higher mortality risks (RR 1.21, 95%CI [1.05-1.39]). Coadministration of verapamil or diltiazem was associated with higher major bleeding risks (RR 1.64, 95%CI [1.31-2.06]), but comparable thromboembolic (RR 1.10, 95%CI [0.75-1.61]) and mortality risks (RR 1.01, 95%CI [0.77-1.33]). CONCLUSION: Given the higher bleeding and mortality risks in NOAC-treated AF patients concomitantly using P-gp/CYP3A4 inhibitors, close monitoring is warranted.
引用
- Grymonprez M, Vanspranghe K, Capiau A, et al. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Br J Clin Pharmacol. 2022. PMID: 35132677. doi:10.1111/bcp.15265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。